Skip to main content

Table 2 Clinical characteristics of 60 patients with rheumatoid arthritis and regression analysis for factors associated with systolic global longitudinal strain

From: Disease activity is associated with LV dysfunction in rheumatoid arthritis patients without clinical cardiovascular disease

Clinical parametersValueAdjusted univariate coefficienta (SE)P-value
Clinical
 Duration of RA (years)9.0 ± 6.8 (2–40)1.68 (0.76)0.02
 HAQ disability index0.55 ± 0.6 (0–2.25)1.1 (0.49)0.58
 Rheumatoid nodule0NANA
 DAS28-CRP2.9 ± 0.9 (1.48–5.66)1.44 (0.72)0.041
 DAS28-ESR3.4 ± 0.9 (1.05–6.25)0.67 (0.43)0.7
 Joint erosion25 (42%)0.8 (0.62)0.09
Medications
 Methotrexate58 (96%)0.03 (0.01)0.79
 Cumulative dose of methotrexate (g)2.9 ± 1.4 (0–5.36)0.26 (0.02)0.47
 Sulfasalazine30 (50%)0.72 (0.13)0.61
 Hydroxychloroquine18 (23%)0.4 (0.27)0.53
 Leflunomide20 (30%)0.74 (0.81)0.8
 Other DMARDs31 (52%)0.1 (0.05)0.72
 Corticosteriod29 (48%)0.7 (0.49)0.93
 Cumulative dose of corticosteroid (g)2.8 ± 4.6(0–23)0.33 (0.09)0.82
 NSAIDs13 (22%)0.92 (0.55)0.44
Laboratory
 CRPb (mg/dL)10.1 ± 15 (0.3–65.2)0.52 (0.38)0.56
 ESRb(mm/hr)30 ± 19 (3–81)0.81 (0.62)0.7
 Positive RF or ACPA45 (75%)0.59 (1.0)1.0
  1. Continuous data are expressed as mean ± SD (min-max), categorical data as n (%)
  2. ACPA Anti-citrullinated peptide antibodies, CRP C-reactive protein, DAS28 Disease Activity Score 28, DMARDs Disease-modifying antirheumatic drugs, ESR Erythrocyte sedimentation rate, HAQ Health assessment questionnaire, RA Rheumatoid arthritis, RF Rheumatoid factor, NA Not available or not applicable
  3. aAdjusted for age, gender, blood pressure, body mass index, heart rate and left ventricular mass index
  4. bLog-transformed